Zacks Investment Research
08 Jun 2026, 16:55 UTC · 21w ago
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
Impact · against what's priced in
Merit Medical (MMSI) shows positive organic growth and strategic expansion into oncology, but these gains are offset by persistent geopolitical risks in China. The stock's significant year-to-date underperformance suggests the market has already heavily discounted the macro headwinds, leaving recent earnings beats as marginal catalysts.
- MMSI+0.10
No priced-in read yet
- In context
The acquisition of View Point Medical and a 7% increase in therapeutic product sales provide growth catalysts, though these are tempered by ongoing trade policy headwinds and macroeconomic pressure in China.
Read from the article alone
